Clinical Study Of Hua Yin Xiao Pi Plaster Combined With Cisplatin Intrapleural Perfusion Chemotherapy In The Treatment Of Malignant Pleural Effusion Of Lung Cancer Treatment

Objective: Observation of Hua Yin Xiao Pi plaster combined with cisplatin Intrapleural Perfusion Combined with systemic chemotherapy for NSCLC patients with malignant pleural effusion KPS score,clinical symptoms,quality of life and influence of serum CEA,VEGF concentration in chest water control effect,before and after the treatment,the evaluation of Hua Yin Xiao Pi plaster combined with cisplatin intrapleural injection combined with chemotherapy on NSCLC patients with malignant pleural effusion clinical efficacy and to explore its mechanism.Methods: Select meets the screening criteria of 66 cases of advanced lung cancer patients with malignant pleural effusion,randomly divided into treatment group and control group(Hua Yin Xiao Pi plaster combined with Cisplatin chest perfusion with systemic chemotherapy)and control group(Cisplatin chest perfusion combined with systemic chemotherapy);each group of 33 cases,observation of two groups of patients with the KPS score,clinical symptoms,quality of life,control of pleural effusion CEA,VEGF value clinical examination index changes and other changes in the value of clinical parameters.Results:(1)KPS score,clinical symptoms and quality of life: compared with before treatment,two groups of patients were significantly improved,there was significant difference(P△<0.01);the comparison between the two groups after treatment,the treatment group than the control group,there was significant difference(P*<0.01);(2)improvement in cough after treatment,the two groups had improved,compared with before treatment,the difference was statistically significant(P△<0.05);the comparison between the two groups after treatment,there was no significant difference between two groups(P*>0.05);equivalent effect;(3)in the improvement of chest pain: after treatment,two groups had improved,compared with treatment before,the difference was statistically significant(P△ <0.05);the comparison between the two groups after treatment,the treatment group improved significantly than the control group,the difference was statistically significant(P*<0.05);4)the serum CEA values compared with the two groups after treatment were improved,compared with before treatment,the difference was statistically significant(P~△<0.01);the comparison between the two groups after treatment,there was no statistically significant difference(P*>0.05),a two group of curative effect;(5)serum VEGF value comparison: the two groups were decreased after treatment,compared with before treatment,there was significant difference(P△<0.01);the comparison between the two groups after treatment,there is obvious statistically significant difference(P*<0.01),the treatment group than the control group;(6)after the treatment of water control comparison: the treatment group total effective rate was 61.3%;the control group total effective rate was 46.7%,there was significant difference(P<0.01),the treatment group than the control group;(7)bone marrow suppression: comparison of the two groups there was no significant difference(P>0.05);(8)there is no obvious difference between two groups of patients with liver and kidney function and other safety indicators;Conclusion: Hua Yin Xiao Pi plaster combined with cisplatin Intrapleural Perfusion Combined with systemic chemotherapy can block non-small cell lung cancer cell invasion and metastasis,reduce serum CEA,VEGF concentration,MPE generation control,thus making the various clinical symptoms of NSCLC and MPE patients significantly reduced,significantly improve the quality of life of patients,improve the prognosis,curative effect is good,is worth clinical promotion.